Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients?

Journal of Clinical Oncology

Volumn 14, Issue 4, 1996, Pages 1245-1251

  Zoubek, A ^a   Dockhorn Dworniczak, B ^a   Delattre, O ^a   Christiansen, H ^a   Niggli, F ^a   Gatterer Menz, I ^a   Smith, T L ^a   Jurgens H ^a   Gadner, H ^a   Kovar, H ^a  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME BREAKAGE; EWING SARCOMA; FEMALE; GENE EXPRESSION REGULATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT;

EID: 9244236526     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.4.1245     Document Type: Article

References (27)

1. Ambros IM, Ambros PF, Strehl S, et al: MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Cancer 67:1886-1893, 1991
2. Horowitz ME, Malawer MM, Delaney TF, et al: Ewing's sarcoma family of tumors: Ewing's sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors, in Pizzo PA, Poplack DG (eds): Principles and Practice of Pediatric Oncology (ed 2). Philadelphia, PA, Lippincott, 1993, pp 795-821
3. Delattre O, Zucman J, Plougastel B, et al: Gene fusion with an ETS-binding domain caused by chromosome translocation in human tumors. Nature 359:162-165, 1992
4. Delattre O, Zucman J, Melot T, et al: The Ewing family of tumors - A subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 331:294-299, 1994
5. Sorensen PHB, Lessnick SL, Lopez-Terrada D, et al: A second Ewing's sarcoma translocation, t(21:22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nature Genetics 6:146-151, 1994
6. Zucman J, Melot T, Desmaze C, et al: Combinatorial generation of variable fusion proteins in the Ewing family of tumors. EMBO J 12:4481-4487, 1993
7. Giovannini M, Biegel JA, Serra M, et al: EWS-Erg and EWS-Fli-1 fusion transcripts in Ewing's sarcoma and primitive neuroectodermal tumors with variant translocations. J Clin Invest 94:489-496, 1994
8. Zoubek A, Pfleiderer C, Salzer-Kunschik M, et al: Variability of EWS-chimaeric transcripts in Ewing tumours: A comparison of clinical and molecular data. Br J Cancer 70:908-913, 1994
9. Dockhorn-Dworniczak B, Schäfer KL, Dantcheva R, et al: Diagnostic value of the molecular genetic detection of the t(11;22) translocation in Ewing's tumours. Virchows Arch 425:107-112, 1994
10. Ohno T, Rao VN, Reddy ES: EWS-Fli1 chimeric protein is a transcriptional activater. Cancer Res 53:5859-5863, 1993
11. Bailly RA, Bosselet R, Zucman J, et al: DNA-binding and transcriptional activation properties of EWS-Fli-1 fusion protein resulting from the t(11;22) translocation in Ewing Sarcoma. Mol Cell Biol 14:3230-3241, 1994
12. Plougastel B, Zucman J, Peter M, et al: Genomic structure of the EWS gene and its relationship to EWSR1, a site of tumor-associated chromosome translocation. Genomics 18:609-615, 1993
13. Meyer D, Wolff CM, Stiegler P, et al: X1-fli, the Xenopus homologue of the fli-1 gene, is expressed during embryogenesis in a restricted pattern evocative of neural crest cell distribution. Mech Dev 44:109-121, 1993
14. Mao X, Miesfeldt S, Yang H, et al: The FLI-1 and EWS-FLI-1 oncoproteins display similar DNA binding specificities. J Biol Chem 269:18216-18222, 1994
15. Jürgens H, Exner U, Gadner H, et al: Multidisciplinary treatment of primary Ewing sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer 61:23-32, 1988
16. Burgert EO, Nesbit ME, Garnsey LA, et al: Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: Intergroup Study IESS-II. J Clin Oncol 8:1540, 1990
17. Burdach S, Jürgens H, Peters C, et al: Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J Clin Oncol 11:1482-1488, 1993
18. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chlorotbrm extraction. Anal Biochem 162:156-159, 1987
19. Jürgens H, Paulussen M, Roessner A, et al: Neural differentiation in small round cell sarcomas of bone in children and adolescents: Implications for treatment? Proc Am Soc Clin Oncol 12:1415, 1993 (abstr)
20. May WA, Lessnick SL, Braun BS, et al: The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol 13:7393-7398, 1993
21. Rao VN, Ohno T, Prasad DD, et al: Analysis of the DNA-binding and transcriptional activation functions of human Fli-1 protein. Oncogene 8:2167-2173, 1993
22. Siddique HR, Rao VN, Lee L, et al: Characterization of the DNA binding and transcriptional activation domains of the erg protein. Oncogene 8:1751-1755, 1993
23. Liang H, Olejniczak ET, Mao X, et al: The secondary structure of the ets domain of human Fli-1 resembles that of the helixturn-helix DNA-binding motif of the Escherichia coli catabolite gene activator protein. Proc Natl Acad Sci USA 91:11655-11659, 1994
24. Kiljedian M, Dreyfuss G: Primary structure and binding activity of the hnRNP U protein: Binding RNA through RGG box. EMBO J 11:2655-2664, 1992
25. Lessnick SL, Braun BS, Denny CT, et al: Multiple domains mediate transformation by the Ewing's sarcoma EWS/Fli-1 fusion gene. Oncogene 10:423-431, 1995
26. Wasylyk B, Hahn SL, Giovane A: The Ets family of transcription factors. Eur J Biochem 211:7-18, 1993
27. Jeon I-S, Davis JN, Braun BS, et al: A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene 10:1229-1234, 1995